Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation
Open Access
- 1 September 2000
- Vol. 47 (3) , 387-396
- https://doi.org/10.1136/gut.47.3.387
Abstract
BACKGROUND Substantial evidence implicates the neuropeptide substance P (SP) in mucosal immunoinflammatory responses. Autoradiographic studies have suggested a disturbance in SP receptor expression in inflammatory bowel disease (IBD). AIMS Because of technical limitations such as poor cellular resolution with autoradiography, we used molecular methods to specifically localise the cellular expression of the neurokinin-1 receptor (NK-1R) in IBD colon, and to quantitate NK-1R mRNA expression levels therein. METHODS In situ hybridisation and immunohistochemistry were used to localise NK-1R mRNA and protein, respectively, in normal, ulcerative colitis (UC), and Crohn's disease (CD) colonic resections. NK-1R mRNA expression levels of normal, UC, and CD mucosal biopsies were quantitated by competitive reverse transcription-polymerase chain reaction. RESULTS NK-1R expression was localised to lamina propria mononuclear cells, epithelium, submucosal vasculature, smooth muscle, and myenteric plexus of normal and IBD colon. No ectopic NK-1R expression was observed in IBD. However, we found increased numbers of NK-1R expressing lymphoid cells in IBD tissue, aberrant negative epithelial expression of NK-1R in UC, and increased expression of NK-1R in CD myenteric plexus. Quantitation of NK-1R mRNA expression in IBD colonic mucosal biopsies revealed marked upregulation of NK-1R mRNA levels compared with non-inflamed mucosal expression levels (pCONCLUSIONS This report demonstrates the strategic localisation and upregulation of NK-1R expression in IBD colon, and thereby suggests the involvement of substance P in the pathophysiological symptoms of IBD.Keywords
This publication has 46 references indexed in Scilit:
- Neurokinin-1 (NK-1) receptor is required in Clostridium difficile- induced enteritis.Journal of Clinical Investigation, 1998
- Substance P augments interleukin-10 and tumor necrosis factor-α release by human cord blood monocytes and macrophagesPublished by Elsevier ,1996
- Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitisGastroenterology, 1995
- Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR)Clinical and Experimental Immunology, 1995
- Changes in neuropeptide‐containing nerves in human colonic mucosa with inflammatory bowel diseasePathology International, 1994
- Substance-P-Mediated Intestinal Inflammation: Inhibitory Effects of CP 96,345 and SMS 201-995Neuroimmunomodulation, 1994
- Progress in the development of potent bombesin receptor antagonistsTrends in Pharmacological Sciences, 1991
- Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseasesDigestive Diseases and Sciences, 1987
- Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophilBiochemical and Biophysical Research Communications, 1981
- Enhancement of phagocytosis — A newly found activity of Substance P residing in its N-terminal tetrapeptide sequenceBiochemical and Biophysical Research Communications, 1980